People who took semaglutide over a slower, more flexible schedule were significantly less likely to experience nausea and to ...

Some health experts view GLP-1s as a promising option for PCOS, which lacks a standard treatment and affects millions of ...

Glucagon-like peptide 1 receptor agonists may offer neuroprotective and survival benefits beyond blood sugar control.

If you’ve been taking Ozempic or Wegovy (both of which contain the active ingredient semaglutide), you might wonder, How long ...

GLP-1 receptor agonists semaglutide and tirzepatide are associated with reduced risks of dementia, stroke, and mortality in adults with type 2 diabetes and obesity, new data show.

GLP-1RA users had a 37% lower risk of developing dementia compared to those on other antidiabetic drugs. Stroke risk reduced ...

Semaglutide, the active ingredient in Ozempic and Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist taken as a ...

Semaglutide, a popular anti-obesity drug, may come with a hidden cost: significant muscle loss, especially in women and older ...

Pointing to Ozempic as a paradigm shift, an elite rehab center is experimenting with GLP-1s to tame many forms of addiction.

Novo Nordisk is in the lead, but not alone. Obesity doctors say they are gearing up for demand, predicted to be high. Some ...

Older age and female sex may be associated with greater muscle loss in adults with obesity prescribed semaglutide, and ...

“Weight loss quality is a new concept….The discussion no longer revolves around the lack of adequate efficacy but rather ...